Fennec Announces Results of Annual Meeting
June 08 2018 - 06:00AM
Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX)
today announced that the nominees listed in the management proxy
circular dated April 30, 2018 (the “Circular”) for the Annual
General and Special Meeting of Shareholders were elected as
directors of the Company at the Annual General and Special Meeting
of Shareholders held in New York, New York on June 7, 2018.
Detailed results of the vote for the election of directors are set
out below:
|
|
|
|
|
Name of Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
Dr. Khalid Islam |
9,766,926 |
92.47% |
795,329 |
7.53% |
Mr. Adrian Haigh |
9,767,181 |
92.47% |
795,074 |
7.53% |
Mr. Chris A. Rallis |
9,765,833 |
92.46% |
796,422 |
7.54% |
Mr. Marco Brughera |
10,558,689 |
99.97% |
3,566 |
0.03% |
Mr. Rostislav Raykov |
10,559,584 |
99.97% |
2,671 |
0.03% |
|
|
|
|
|
Shareholders voted 99.90% in favour of
appointing Haskell & White LLP as auditors and authorizing the
directors to fix the auditor remuneration, 97.46% in favour of the
compensation paid to the Company’s named executive officers, and
92.27% in favour of the extension of certain outstanding options
held by certain of the Company’s officers.
For further information, please contact:
Rosty Raykov Chief Executive Officer Fennec Pharmaceuticals Inc.
T: (919) 636-5144
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From Mar 2023 to Mar 2024